Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 5/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420607 | 0.83 | GPR3 (0.46) | GPR3PDE2AMAPTKIF11FFAR4 | |
| SCHEMBL30628388 | 0.83 | GPR3 (0.46) | GPR3PDE2AMAPTKIF11FFAR4 | |
| SCHEMBL22714098 | 0.83 | GPR3 (0.48) | GPR3PDE2AMAPTKIF11CES1 | |
| SCHEMBL7711840 | 0.82 | KIF11 (0.39) | GPR3PDE2AKIF11 | |
| SCHEMBL787543 | 0.78 | SOS1 (0.41) | MAPTTRPA1LMNACYP1A2CYP3A4 | |
| SCHEMBL462815 | 0.78 | GPR3 (0.44) | GPR3MAPTKIF11FFAR4CES1 | |
| SCHEMBL326580 | 0.78 | GPR3 (0.44) | GPR3MAPTKIF11RAB9ALMNA | |
| SCHEMBL6411536 | 0.78 | GPR3 (0.44) | GPR3MAPTKIF11CES1NPC1 | |
| SCHEMBL31371274 | 0.78 | GPR3 (0.44) | GPR3PDE2AMAPTKIF11CES1 | |
| SCHEMBL1275598 | 0.78 | GPR3 (0.44) | GPR3MAPTKIF11FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577242-B2 | Pyrrolopyridine and imidazopyridine antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| EP-4110777-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) | 2023-01-04 | — | — | EP | disclosed |
| CN-115175909-A | Pyrrolopyridine and imidazopyridine antiviral compounds | 鲁汶天主教大学 | 2022-10-11 | — | — | CN | disclosed |
| EP-3643709-B1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| EP-3643709-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
| EP-3214081-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2017-09-06 | — | — | EP | disclosed |
| EP-1951721-A1 | 3 -MONOSUBSTITUTED TROPANE DERIVATIVES AS NOCICEPTIN RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053435-A1 | 3 -MONOSUBSTITUTED TROPANE DERIVATIVES AS NOCICEPTIN RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | SARS1, TPI1, TPMT | GPR3 4335/4885PDE2A 1679/4885MAPT 33/4885 |
| US-12577242-B2 | Pyrrolopyridine and imidazopyridine antiviral compounds | SARS1, TPMT, ZC3HAV1 | GPR3 3374/4885PDE2A 3311/4885MAPT 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.